700 results about "Monoclonal antibody agent" patented technology

The invention discloses a human SARS-CoV-2 monoclonal antibody. The preparation method of the human SARS-CoV-2 monoclonal antibody comprises the steps: adopting SARS-CoV Nucleocapsid recombinant protein as immunogen, immunizing BALB/c mice, performing fusion and subcloning on spleen cells and myeloma cells of mice, then performing a large amount of repeated screening and domestication of cell lines through commercialized products SARS-CoV-2 Nucleocapsid and MERS Nucleocapsid so as to obtain a hybridoma cell line capable of secreting the SARS-CoV-2-resistant N monoclonal antibody with high affinity and high specificity finally and successfully, and finally performing ascites preparation and purification so as to obtain the monoclonal antibody, wherein the amino acid sequence of the SARS-CoVNucleocapsid recombinant protein is shown in SEQ ID No. 1. The invention also discloses application of the monoclonal antibody in preparation of SARS-CoV-2 virus detection products and preparation ofdrugs for inhibiting the SARS-CoV-2 viruses. The monoclonal antibody can be used for detecting the SARS-CoV-2 in human throat swabs/pulmonary secretions and other samples by using a double-antibody sandwich method, and can be applied to diagnosis and prevention and control of SARS-CoV-2 virus infection and scientific researches of viruses and other study.

Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

The invention relates to isolated fully human monoclonal antibodies having specificity for human NKG2D and compositions thereof. The invention further relates to methods for using such antibodies in treating diseases or conditions such as cancer, autoimmune disease, or infectious disease.

The present invention belongs to the field of biological detection. Multi-line immunochromatographic test strip for semi-quantitative detection of aflatoxin B₁ comprises a paperboard, wherein a water-absorbing pad, a detection pad, a gold-labeled pad and a sample pad are adhered sequentially on one surface of the paperboard from top to bottom, wherein each adjacent pads is overlapped and connected, the detection pad uses a nitrocellulose film as a backing pad, the nitrocellulose film is provided with a transverse control line, a test line I, a test line II and a test line III, wherein the control line is coated with a rabbit anti-mouse polyclonal antibody, and the test line I, test line II and test line III are coated with aflatoxin B₁-bovine serum albumin conjugate (AFB₁-BSA), respectively: and the gold-labeled pad is transversely coated with a nanogold-labeled anti-aflatoxin B₁ monoclonal antibody. Said test strip is used for semi-quantitative detection of aflatoxin B₁, and is characterized by quick detection, simple procedure and high sensitivity.

The invention discloses a preparation method of agarose immune magnetic microspheres and applications thereof, and relates to a preparation method of microspheres and applications thereof, which solves the technical problems that an existing purified monoclonal antibody is complex in process, is low in yield, and is high in cost, and coupling agents are hypertoxic. The preparation method comprises the following steps of: 1. preparing a ferric oleate precurser; 2. preparing a magnetic fluid; 3. preparing an oil phase and a water phase; 4. preparing agarose magnetic microspheres; 5. preparing activated and crosslinked agarose magnetic microspheres; 6. preparing agarose magnetic microspheres joined with spacer arms; and 7. preparing agarose immune magnetic microspheres. The agarose immune magnetic microspheres provided by the invention are used for purifying genetic engineering recombination trastuzumab monoclonal antibodies. The agarose immune magnetic microspheres prepared by the invention are used for the field of separating and purifying the monoclonal antibodies.

The invention discloses an enzyme linked immunosorbent assay kit for combined diagnosis of the gastrosis or evaluation of gastric cancer risks and a preparation method thereof. The kit comprises a micropore plate coated with an antibody against a pepsin antigen I or an antibody against a pepsin antigen II, an enzyme labeled antibody, a color-developing agent, a stop solution and a concentrated cleaning solution, wherein the pepsin antigen I or the pepsin antigen II is a natural protein obtained from extraction of human gastric mucosa tissue. The kit disclosed by the invention adopts a mouse immunized with pepsinogen I and pepsinogen II which are separated from human gastric mucosa to prepare immunogen of a monoclonal antibody, the used standard sample also adopts the pepsin antigen I or the pepsin antigen II separated from the human gastric mucosa, thereby the defects caused by adopting different structures of animal pepsinogen and human pepsinogen are filled. The kit can be used for accurately diagnosing the gastrosis or early gastric cancer and has the advantages of high sensitivity, strong specificity, good accuracy and the like.

The invention discloses a rudimental immune antibody which is used to detect organic phosphorus pesticide residue and its application, the character of the invention is using diethyl phosphonic acid acetic acid as hapten, produce artificial immunogen through coupling with bovine serum albumin(BSA), and produce several clone antibody through immune Zelanian giant blanc or produce mono clone antibody through chmice immune, cell amalgamation, filtration, clone planting and other steps, the several and single antibody can be used to indirect emulative ELISA, direct ELISA, or immune test paper to detect the rudimental phosphorus pesticide. The excellences of the invention including: the selected hapten has several organic phosphorus pesticides general structure, the structure reforming is not necessary, it can immune animal after coupling with protein, it can also be used to detect organic phosphorus pesticide in food and water source, this show the rapid and convenient of the immune detecting tehchnology.

Methods for differentially identifying cells in an instrument employ compositions containing a combination of selected antibodies and fluorescent dyes having different cellular distribution patterns and specificities, as well as antibodies and fluorescent dyes characterized by overlapping emission spectra which form non-compensatable spectral patterns. When utilizing the compositions described herein consisting of fluorescent dyes and fluorochrome labeled antibodies with overlapping spectra that cannot be separated or distinguished based upon optical or electronic compensation means, a new fluorescent footprint is established. This new fluorescent footprint is a result of the overlapping spectra and the combined cellular staining patterns of the dyes and fluorochrome labeled antibodies chosen for the composition. The new fluorescent footprint results in histogram patterns that are useful for the identification of additional cell populations or subtypes in hematological disease.

The invention discloses a phage display antibody library and five strains of screened antibodies capable of being combined with S protein of novel coronavirus SARS-CoV-2. Mutation is introduced into an ultra-variable region of an antibody variable region based on synthetic biology and a phage display technology, and a gene is transferred into escherichia coli, so that a synthetic antibody librarycontaining 108 kinds of antibodies is constructed; the phage display antibody library provided by the invention can perform screening to obtain the antibody with the specificity and the detection function, so that powerful resources of biological research and medical diagnosis are expanded; and the five strains of antibodies capable of being combined with the S protein of the novel coronavirus arefurther screened out and can be used for detecting the virus, part of the antibodies can block combination of the virus and cells, and the antibodies have the capacity of neutralizing novel coronavirus infectivity, can be used for preparing a novel coronavirus detection product, preparing a drug for inhibiting the novel coronavirus and preparing a pharmaceutical preparation for preventing or treating diseases caused by the novel coronavirus, and have a wide application prospect.

The invention discloses an acute myocardial infarction diagnosis-oriented biosensor and a preparation method thereof. The sensor comprises a sensor matrix with a field effect tube (FET) structure, and a micro channel system layer, wherein the sensor matrix comprises a silicon-on-insulator (SOI) silicon chip; the surface of the silicon chip is provided with a passivation layer, silicon nanowires of which the surfaces are coupled with monoclonal antibody modified by acute myocardial infarction marker protein, and electrodes; at least local surfaces of the nanowires are exposed in a micro channel in the micro channel system layer; the micro channel is communicated with a sample solution inlet and a sample solution outlet on the micro channel system layer; and the sensor is prepared by a micro-nano processing method. The sensor can detect various marker proteins in serum by an electrical measurement means so as to acquire the degree of myocardial infarction attack. The biosensor can quickly and sensitively detect the myocardial infarction, has high response speed and diagnostic rate, and is suitable for the field of clinical medical detection.

It is a poison multiple and combination test agent box and its process method, which comprise plastic shell and test paper bar. The plastic shell comprises upper cover and down cover, wherein, the upper cover comprises specimen adding holes, test result display hole and fix mark hole; the down cover is set with flute. The test paper comprises test specimen area, test result display area and water absorption area, wherein, the test specimen area comprises glue gold and filter paper; the test result display area comprises pyroxylin film, C line control area with sheep and rabbit polyclonal antibody, test display area with heroin antigen and test display area with methyl amphetamine antigen. The water absorption area is set with absorption paper and fix mark.

A novel coronavirus earlier-stage screening method disclosed by the invention can be used for detecting the novel coronavirus, and is particularly used for screening the SARS-CoV-2IgA antibody in theearly stage. A kit comprises an SARS-CoV-2 magnetic bead coating material used as R1, containing a magnetic bead coating material trihydroxymethyl aminomethane buffer solution coated by an SARS-CoV-2recombinant antigen, wherein the pH value is 7.1-7.4; and an acridinium ester marker of the anti-human IgA antibody as R2, wherein the acridinium ester marker is a 2-(N-morpholine) ethanesulfonic acidbuffer solution containing an acridinium ester labeled mouse anti-human IgA monoclonal antibody. The kit and the SARS-CoV-2IgA antibody immunoassay reagent disclosed by the invention can be used forsupplementing and diagnosing new coronal pneumonia at an earlier stage, and have the characteristic of accurate detection result.

The invention belongs to the field of medicine, particularly relates to a diagnostic technique of heart failure, and specifically relates to a B cell epitope peptide segment of amino-terminal pro-brain natriuretic peptide. An amino acid sequence is shown in SEQ ID NO:4 or SEQ ID NO:5. The prepared specific antibody can be used as a diagnostic reagent of heart failure. The amino-terminal pro-brain natriuretic peptide prepared by the invention is high-purity monomer recombinant protein of the amino-terminal pro-brain natriuretic peptide. The protein can be used for immunogen and screening collagen prepared from an antibody, and can be simultaneously used as a calibrator when the amino-terminal pro-brain natriuretic peptide is built to carry out quantitative detection. A monoclonal antibody prepared by immune mice at the B cell epitope peptide segment of the amino-terminal pro-brain natriuretic peptide has the advantages of high purity (SDS-PAGE detection purity greater than 96%), high valence (the valence of ELISA up to 1:512000), good specificity, mass preparation, and the like.

The invention relates to a novel magnetic molecular targeted ultrasound contrast agent, in particular to a gas-wrapped magnetic liposome microsphere suspension with the mean diameter of 1-4 micrometers and a preparation method thereof. The preparation method of the magnetic molecular targeted ultrasound contrast agent microsphere comprises a condition that a lipid layer of the microsphere and/or the surface of the lipid layer contains (or connects) magnetic response materials. A contrast agent microsphere wall material contains phospholipids, polyethylene glycol (PEG), PEG phospholipid polymers, biotinylated and/or polypeptide modificatory PEG phospholipid polymer, poloxamer, ligands (monoclonal antibodies or polypeptide, and the like) and the magnetic response materials and/or avidin bridging materials, wherein the ligand (monoclonal antibodies or polypeptide, and the like) has specific affinity to target molecules, the wrapped gas is a fluorine carbon gas, and a solvent is an aqueous medium (distilled water). The invention also provides the preparation method of the magnetic molecular targeted ultrasound contrast agent microsphere, which comprises a condition that the specific ligand is connected with the microsphere in a covalence and avidin bridging way. The novel magnetic molecular targeted ultrasound contrast agent has good targeted developing effect, can be used for evaluating the change of vessel endothelial molecules of an arterious and venous system of an organic tissue and has good application prospect in treatment.

The invention provides a novel coronavirus detection test strip as well as a preparation method and application thereof. The test strip comprises a binding pad and an analysis membrane, and the binding pad is coated with a luminescent substance labeled 2019-nCoV recombinant antigen and a mouse anti-human HCG monoclonal antibody; a T2 detection line, a T1 detection line and a quality control line are sequentially arranged on the analysis membrane along the chromatography direction; the T2 detection line is coated with a mouse anti-human IgG monoclonal antibody, the T1 detection line is coated with a mouse anti-human IgA monoclonal antibody and a mouse anti-human IgM monoclonal antibody, and the quality control line is coated with a goat anti-mouse IgG polyclonal antibody. The test paper card can simultaneously determine the positive conditions of IgA antibody, IgM antibody and IgG antibody in serum of a patient, can more accurately detect the early antibody level condition in the body of the patient, assists in judging different periods of novel coronavirus infection of the patient, and improves the sensitivity and specificity of novel coronavirus detection.